FindTrial
Sign In

To Study the Effect of Topical Losartan Eye-drops in Patients with Corneal Opacity in Terms of Decrease in Corneal Opacity and Scarring and Improvement in Vision.

Effect of Topical Losartan in Patients with Corneal Opacity: A Pilot Study. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/10/096242
Enrollment
60
Registered
2025-10-21
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H179- Unspecified corneal scar and opacity

Interventions

Intervention1: USE OF TOPICAL LOSARTAN 0.08% EYE DROPS IN PATIENTS WITH CORNEAL OPACITIES: TOPICAL LOSARTAN 0.08% EYE DROPS WILL BE PUT 6 TIMES A DAY BY PATIENTS WITH CORNEAL OPACITY Control Interve

Sponsors

DR RP CENTRE FOR OPHTHALMIC SCIENCES
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Consenting adults (age above 18 years) with corneal opacity due to Keratitis, Ocular Trauma, Trachoma

Exclusion criteria

Exclusion criteria: 1.Patients having active ulcer. 2.Patients having active inflammation. 3.Patients having active infection. 4.Patients not willing to participate. 5.Patients on systemic medication.

Design outcomes

Primary

MeasureTime frame
Effect of intervention on corneal opacity and scarring in terms of 1.Area of opacity as seen on slit lamp biomicroscopy. 2.Depth of scarring as seen on AS-OCT. 3.Scheimpflug-based Corneal Densitometry values. 4.Improvement in visual acuity.Timepoint: Baseline, 2 weeks, 4 weeks, 12 weeks and 16 weeks.—

Secondary

MeasureTime frame
NILTimepoint:—

Countries

India

Contacts

Public ContactDR NOOPUR GUPTA

DR RP CENTRE OF OPHTHALMIC SCIENCE AIIMS

noopurgupta@hotmail.com01126593111

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026